|
ATE448226T1
(de)
|
2000-09-01 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Aza heterocyclische derivate und ihre therapeutische verwendung
|
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
|
DE60115069T2
(de)
*
|
2000-09-11 |
2006-08-03 |
Chiron Corp., Emeryville |
Chinolinonderivate als tyrosin-kinase inhibitoren
|
|
US7642278B2
(en)
*
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
|
US7064215B2
(en)
*
|
2001-07-03 |
2006-06-20 |
Chiron Corporation |
Indazole benzimidazole compounds
|
|
EP1460067A4
(en)
*
|
2001-11-26 |
2005-12-07 |
Takeda Pharmaceutical |
BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
|
|
US6822097B1
(en)
*
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
|
MXPA04012440A
(es)
*
|
2002-06-12 |
2005-04-28 |
Abbott Lab |
Antagonistas de receptor de hormona concentradora de melanina.
|
|
DE10238002A1
(de)
|
2002-08-20 |
2004-03-04 |
Merck Patent Gmbh |
Benzimidazolderivate
|
|
EP1539754A4
(en)
*
|
2002-08-23 |
2009-02-25 |
Novartis Vaccines & Diagnostic |
BENZIMIDAZOCHINOLINONE AND ITS USE
|
|
CN100526312C
(zh)
*
|
2002-08-23 |
2009-08-12 |
诺华疫苗和诊断公司 |
苯并咪唑喹啉酮及其应用
|
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
AU2003275282A1
(en)
*
|
2002-09-30 |
2004-04-23 |
Bristol-Myers Squibb Company |
Novel tyrosine kinase inhibitors
|
|
SG148864A1
(en)
*
|
2002-11-13 |
2009-01-29 |
Chiron Corp |
Methods of treating cancer and related methods
|
|
CN100377709C
(zh)
*
|
2002-11-13 |
2008-04-02 |
希龙公司 |
受体酪氨酸激酶抑制剂的制药用途及相关检测方法
|
|
WO2004069160A2
(en)
*
|
2003-01-28 |
2004-08-19 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
WO2004087153A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
US7627675B2
(en)
*
|
2003-05-01 |
2009-12-01 |
Cisco Technology, Inc. |
Methods and devices for regulating traffic on a network
|
|
EP1660087A2
(en)
*
|
2003-07-22 |
2006-05-31 |
Janssen Pharmaceutica N.V. |
Quinolinone derivatives as inhibitors of c-fms kinase
|
|
EP1648455A4
(en)
|
2003-07-23 |
2009-03-04 |
Exelixis Inc |
MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
|
|
US20050209247A1
(en)
*
|
2003-11-07 |
2005-09-22 |
Chiron Corporation |
Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
|
|
CN1976706B
(zh)
*
|
2003-11-07 |
2012-01-18 |
诺华疫苗和诊断公司 |
抑制fgfr3及治疗多发性骨髓瘤
|
|
EP1684762A4
(en)
*
|
2003-11-13 |
2009-06-17 |
Ambit Biosciences Corp |
UREA DERIVATIVES AS MODULATORS OF KINASE
|
|
WO2005053692A1
(en)
*
|
2003-12-01 |
2005-06-16 |
The Scripps Research Institute |
Advanced quinolinone based protein kinase inhibitors
|
|
EP1718306A2
(en)
*
|
2004-02-20 |
2006-11-08 |
Chiron Corporation |
Modulation of inflammatory and metastatic processes
|
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
US7521446B2
(en)
|
2005-01-13 |
2009-04-21 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
US7759342B2
(en)
|
2005-01-13 |
2010-07-20 |
Signal Pharmaceuticals, Llc |
Methods of treatment and prevention using haloaryl substituted aminopurines
|
|
US7723340B2
(en)
|
2005-01-13 |
2010-05-25 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
EP2301546B1
(en)
*
|
2005-01-27 |
2014-09-10 |
Novartis AG |
Treatment of metastasized tumors
|
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
SI1858920T1
(sl)
|
2005-02-18 |
2016-07-29 |
Glaxosmithkline Biologicals S.A. |
Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
|
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド |
尿路病原性菌株由来の抗原
|
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
EP1885187B1
(en)
*
|
2005-05-13 |
2013-09-25 |
Novartis AG |
Methods for treating drug resistant cancer
|
|
EP2465857B1
(en)
|
2005-05-17 |
2014-06-04 |
Novartis AG |
Methods for synthesizing heterocyclic compounds
|
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
|
BRPI0611375A2
(pt)
|
2005-05-23 |
2010-08-31 |
Novartis Ag |
formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
|
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
|
EP1909564A4
(en)
|
2005-07-18 |
2010-06-30 |
Novartis Ag |
SMALL ANIMAL MODEL FOR HCV REPLICATION
|
|
AU2006301292A1
(en)
*
|
2005-10-14 |
2007-04-19 |
F. Hoffmann-La Roche Ag |
Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine
|
|
CA2628152C
(en)
|
2005-11-04 |
2016-02-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
CN102755645A
(zh)
|
2005-11-04 |
2012-10-31 |
诺华疫苗和诊断有限公司 |
佐剂配制的包含细胞因子诱导剂的流感疫苗
|
|
NZ594482A
(en)
|
2005-11-04 |
2012-11-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
|
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
|
DE102005054904A1
(de)
*
|
2005-11-17 |
2007-05-24 |
Wacker Polymer Systems Gmbh & Co. Kg |
Verfahren zur Herstellung polyvinylalkoholstabilisierter Latices
|
|
NZ567550A
(en)
*
|
2005-11-29 |
2011-08-26 |
Novartis Ag |
Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
|
|
KR20080080525A
(ko)
|
2005-12-08 |
2008-09-04 |
노파르티스 아게 |
유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
PL2478916T3
(pl)
|
2006-01-27 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
TW200803855A
(en)
*
|
2006-02-24 |
2008-01-16 |
Kalypsys Inc |
Quinolones useful as inducible nitric oxide synthase inhibitors
|
|
AR059898A1
(es)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
|
|
US8063063B2
(en)
*
|
2006-03-23 |
2011-11-22 |
Novartis Ag |
Immunopotentiating compounds
|
|
ES2536426T3
(es)
*
|
2006-03-23 |
2015-05-25 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores
|
|
EP2010530A2
(en)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Methods for the preparation of imidazole-containing compounds
|
|
CN101448523A
(zh)
|
2006-03-24 |
2009-06-03 |
诺华疫苗和诊断有限两合公司 |
无需冷藏储存流感疫苗
|
|
EP2382988A1
(en)
|
2006-03-31 |
2011-11-02 |
Novartis AG |
Combined mucosal and parenteral immunization against HIV
|
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
|
AU2007240496A1
(en)
|
2006-04-19 |
2007-11-01 |
Novartis Ag |
Indazole compounds and methods for inhibition of CDC7
|
|
PT2054431E
(pt)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Confórmeros de adesinas bacterianas
|
|
US8138205B2
(en)
|
2006-07-07 |
2012-03-20 |
Kalypsys, Inc. |
Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
|
|
CA2657093A1
(en)
|
2006-07-07 |
2008-01-10 |
Steven P. Govek |
Bicyclic heteroaryl inhibitors of pde4
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
EP4585610A3
(en)
|
2006-09-11 |
2025-09-24 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
PT2121011E
(pt)
|
2006-12-06 |
2014-07-31 |
Novartis Ag |
Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
|
NZ580327A
(en)
*
|
2007-04-03 |
2012-02-24 |
Array Biopharma Inc |
IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
|
|
CN101679357A
(zh)
*
|
2007-05-09 |
2010-03-24 |
辉瑞大药厂 |
取代的杂环衍生物及其组合物和作为抗菌剂的药物用途
|
|
KR20100045437A
(ko)
|
2007-06-27 |
2010-05-03 |
노파르티스 아게 |
첨가물이 적은 인플루엔자 백신
|
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
PL2200985T3
(pl)
|
2007-09-14 |
2011-12-30 |
Ortho Mcneil Janssen Pharmaceuticals Inc |
1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
|
|
SI2203439T1
(sl)
|
2007-09-14 |
2011-05-31 |
Ortho Mcneil Janssen Pharm |
1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
EP2240475B1
(en)
|
2007-12-20 |
2013-09-25 |
Novartis AG |
Thiazole derivatives used as pi 3 kinase inhibitors
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
JP5518041B2
(ja)
|
2008-03-18 |
2014-06-11 |
ノバルティス アーゲー |
インフルエンザウイルスワクチン抗原の調製における改良
|
|
PE20091628A1
(es)
*
|
2008-03-19 |
2009-11-19 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
|
|
EP2344470B1
(en)
|
2008-09-02 |
2013-11-06 |
Janssen Pharmaceuticals, Inc. |
3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
|
|
JP5690277B2
(ja)
|
2008-11-28 |
2015-03-25 |
ジャンセン ファーマシューティカルズ， インコーポレイテッド． |
代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
|
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
|
EP3263128A3
(en)
|
2009-04-14 |
2018-01-24 |
GlaxoSmithKline Biologicals S.A. |
Compositions for immunising against staphylococcus aureus
|
|
USH2283H1
(en)
|
2009-04-27 |
2013-09-03 |
Novartis Ag |
Vaccines for protecting against influenza
|
|
US8492374B2
(en)
|
2009-04-29 |
2013-07-23 |
Industrial Technology Research Institute |
Azaazulene compounds
|
|
AR078411A1
(es)
|
2009-05-07 |
2011-11-09 |
Lilly Co Eli |
Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
|
|
CN102439008B
(zh)
|
2009-05-12 |
2015-04-29 |
杨森制药有限公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
|
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
BRPI1010831A2
(pt)
|
2009-05-12 |
2016-04-05 |
Addex Pharmaceuticals Sa |
derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
US10988511B2
(en)
|
2009-07-07 |
2021-04-27 |
Glaxosmithkline Biologicals Sa |
Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
|
|
CA2768186A1
(en)
|
2009-07-15 |
2011-01-20 |
Novartis Ag |
Rsv f protein compositions and methods for making same
|
|
AU2010272243A1
(en)
|
2009-07-16 |
2012-03-08 |
Novartis Ag |
Detoxified Escherichia coli immunogens
|
|
JPWO2011033588A1
(ja)
*
|
2009-09-18 |
2013-02-07 |
株式会社アドバンテスト |
試験装置および試験方法
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
WO2011075620A1
(en)
|
2009-12-18 |
2011-06-23 |
Novartis Ag |
Method for treating haematological cancers
|
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
|
CN102834094B
(zh)
|
2010-04-16 |
2015-05-06 |
诺华有限公司 |
有机化合物的组合产品及其制药用途
|
|
BR112012026289A2
(pt)
|
2010-04-16 |
2016-07-12 |
Novartis Ag |
composto orgânico para uso no tratamento de câncer do fígado
|
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
AR081776A1
(es)
|
2010-06-30 |
2012-10-17 |
Novartis Ag |
Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
JP6039559B2
(ja)
|
2010-09-02 |
2016-12-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体
|
|
JO3062B1
(ar)
|
2010-10-05 |
2017-03-15 |
Lilly Co Eli |
R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
|
|
AU2011328203B2
(en)
|
2010-11-08 |
2015-03-19 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
|
US9271967B2
(en)
|
2010-11-08 |
2016-03-01 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
|
ES2536433T3
(es)
|
2010-11-08 |
2015-05-25 |
Janssen Pharmaceuticals, Inc. |
Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
|
|
WO2012103361A1
(en)
|
2011-01-26 |
2012-08-02 |
Novartis Ag |
Rsv immunization regimen
|
|
MX343706B
(es)
|
2011-01-31 |
2016-11-18 |
Novartis Ag |
Derivados heterocíclicos novedosos.
|
|
AU2012229107A1
(en)
|
2011-03-17 |
2013-09-19 |
Novartis Ag |
FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
|
|
CA2835644C
(en)
|
2011-05-13 |
2021-06-15 |
Novartis Ag |
Pre-fusion rsv f antigens
|
|
MX2013013437A
(es)
|
2011-05-19 |
2013-12-06 |
Novartis Ag |
4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
JP2014526506A
(ja)
|
2011-09-15 |
2014-10-06 |
ノバルティス アーゲー |
中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用
|
|
PT2771342T
(pt)
|
2011-10-28 |
2016-08-17 |
Novartis Ag |
Derivados de purina e o seu uso no tratamento de doença
|
|
WO2013063003A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
|
RU2636350C2
(ru)
|
2011-11-07 |
2017-11-22 |
Новартис Аг |
МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
|
|
EP2809312A1
(en)
|
2012-01-31 |
2014-12-10 |
Novartis AG |
Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
|
|
WO2013173283A1
(en)
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
|
IN2014DN10801A
(https=)
|
2012-07-11 |
2015-09-04 |
Novartis Ag |
|
|
TR201808684T4
(tr)
|
2012-10-02 |
2018-07-23 |
Glaxosmithkline Biologicals Sa |
Lineer olmayan sakarit konjügatları.
|
|
WO2014058785A1
(en)
|
2012-10-10 |
2014-04-17 |
Novartis Ag |
Combination therapy
|
|
CN103804353A
(zh)
*
|
2012-11-01 |
2014-05-21 |
常辉 |
一类治疗精神分裂症的化合物及其用途
|
|
CN111249455A
(zh)
|
2012-11-30 |
2020-06-09 |
葛兰素史密丝克莱恩生物有限公司 |
假单胞菌抗原和抗原组合
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
EP2956138B1
(en)
|
2013-02-15 |
2022-06-22 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
MX368903B
(es)
|
2013-02-20 |
2019-10-21 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
EP3003377A1
(en)
|
2013-05-31 |
2016-04-13 |
Novartis AG |
Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
|
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
|
SG10202103278TA
(en)
|
2013-10-14 |
2021-04-29 |
Eisai R&D Man Co Ltd |
Selectively substituted quinoline compounds
|
|
ES2670550T3
(es)
|
2013-10-14 |
2018-05-30 |
Eisai R&D Management Co., Ltd. |
Derivados de quinolina selectivamente sustituidos
|
|
US9458169B2
(en)
|
2013-11-01 |
2016-10-04 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
CN105979947A
(zh)
|
2013-12-06 |
2016-09-28 |
诺华股份有限公司 |
α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
|
|
MX386697B
(es)
|
2014-01-21 |
2025-03-19 |
Janssen Pharmaceutica Nv |
Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
|
|
ME03518B
(me)
|
2014-01-21 |
2020-04-20 |
Janssen Pharmaceutica Nv |
Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
|
|
CA2945263A1
(en)
|
2014-04-09 |
2015-10-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
SG11201610500WA
(en)
|
2014-06-17 |
2017-01-27 |
Vertex Pharma |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
|
CN107075480A
(zh)
|
2014-07-09 |
2017-08-18 |
Tc生物制药有限公司 |
γδT细胞及其用途
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
KR101693781B1
(ko)
*
|
2014-10-06 |
2017-01-09 |
한양대학교 에리카산학협력단 |
다이플루오로알킬기가 도입된 방향족 화합물의 제조 방법
|
|
US20170304313A1
(en)
|
2014-10-06 |
2017-10-26 |
Novartis Ag |
Therapeutic Combination For The Treatment Of Cancer
|
|
CN104774221B
(zh)
*
|
2015-03-19 |
2017-02-08 |
广西师范大学 |
喹啉酮衍生物的金属配合物及其合成方法及应用
|
|
CN104817535A
(zh)
*
|
2015-03-19 |
2015-08-05 |
广西师范大学 |
一种喹啉酮衍生物及其合成方法及应用
|
|
CN104725431B
(zh)
*
|
2015-03-19 |
2017-05-17 |
广西师范大学 |
喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
EP3333157B1
(en)
|
2015-08-07 |
2020-12-23 |
Harbin Zhenbao Pharmaceutical Co., Ltd. |
Vinyl compounds as fgfr and vegfr inhibitors
|
|
AR105911A1
(es)
|
2015-09-03 |
2017-11-22 |
Forma Therapeutics Inc |
Inhibidores de hdac8 bicíclicos fusionados [6,6]
|
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
|
EP3231434A1
(en)
|
2016-04-14 |
2017-10-18 |
Fundacio Centre de Regulacio Genomica |
Method of treatment of parkinsonism
|
|
AU2017324713B2
(en)
|
2016-09-08 |
2020-08-13 |
KALA BIO, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
US10336767B2
(en)
|
2016-09-08 |
2019-07-02 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
CN107935858B
(zh)
*
|
2016-10-12 |
2020-09-08 |
利尔化学股份有限公司 |
5-氟-2-硝基苯酚的制备方法
|
|
AU2018291687B2
(en)
|
2017-06-27 |
2022-07-14 |
Janssen Pharmaceutica Nv |
New quinolinone compounds
|
|
KR102763767B1
(ko)
|
2017-11-24 |
2025-02-05 |
얀센 파마슈티카 엔브이 |
피라졸로피리디논 화합물
|
|
AU2018370904B2
(en)
|
2017-11-24 |
2023-09-21 |
Janssen Pharmaceutica Nv |
Pyrazolopyridinone compounds
|
|
PT3722282T
(pt)
|
2017-12-07 |
2024-10-04 |
Harbin Zhenbao Pharmaceutical Co Ltd |
Forma de sal e forma cristalina que servem como compostos inibidores de fgfr e vegfr, e método de preparação para esse fim
|
|
CN109553534A
(zh)
*
|
2018-11-27 |
2019-04-02 |
常州大学 |
一种2-硝基-4-甲氧基苯甲酸的制备方法
|
|
WO2020135483A1
(en)
|
2018-12-26 |
2020-07-02 |
Janssen Pharmaceutica Nv |
Thienopyridinone compounds
|
|
US10835531B1
(en)
|
2019-06-18 |
2020-11-17 |
Oncology Venture ApS |
Methods for predicting drug responsiveness in cancer patients
|
|
GB201909191D0
(en)
*
|
2019-06-26 |
2019-08-07 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
AU2022379973A1
(en)
|
2021-11-08 |
2024-06-27 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
|
WO2025085233A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Ensem Therapeutics, Inc. |
Novel derivatives of quinolinones, and compositions and methods thereof
|